NewSelf Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 8.6/10
Best for: semaglutide at $100/month, 47% below the typical price
NewSelf falls below our bar on oversight: the FDA has issued it a warning letter. Read the breakdown below before you give it money.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Prices checked August 2026
NewSelf sells compounded semaglutide+ with B12 and glycine from $99.97/mo and compounded tirzepatide+ with B6 and glycine from $144.49/mo. It is LegitScript certified and available in 48 states plus Puerto Rico, using 503A licensed pharmacies with third-party testing.
Is NewSelf legit?
NewSelf is a real, operating US company, and the FDA has issued it a warning letter. The letter is summarized at the top of this review. Read what it alleges before you decide, and raise it with the clinician who would prescribe for you. We rate NewSelf 8.6/10 overall.
Is there a NewSelf promo or coupon code?
We know of no promo or coupon code for NewSelf. Its listed price is $100 a month. Coupon sites advertising "NewSelf discount codes" are not a source we can vouch for, and any genuine offer shows at checkout without a code.
See how NewSelf compares on our rankings of the best semaglutide providers and the best tirzepatide providers.
Vetted alternatives to NewSelf
Enhance MD
Best for: knowing which pharmacy fills the vial: it names Tru Meds Rx
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
NewSelf at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $100/mo (All dosages same price)
- Pricing model
- Flat: the price stays the same as the dose goes up
- What's included
- Medication · Consult · Shipping
- Availability
- 49 states
- FDA status
- 1 FDA warning letter (details below)
How NewSelf scores
Six columns, each one computed from something NewSelf has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
9.4/10$100/month is 46% below the $185 median for compounded semaglutide across the sellers we compare.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10A price is shown before the questionnaire starts.
Trust & Safety15%
5.5/10The FDA has issued it a warning letter. No pharmacy is named for its prescriptions. It shows a price before asking for health information. It lists the states it serves.
Accessibility10%
9.8/10Serves 49 of 50 states.
Support10%
7.0/10The price covers the medication, clinician visits and shipping.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on NewSelf
Last checked August 2026- Checked the listed price across 4 dose or plan tiers
- Checked state coverage: all 50
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for NewSelf
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
What signing up with NewSelf involves
What to expect on the way to a prescription: where the price appears, who fills the medication, and what the monthly price covers. It is not medical advice, and a clinician makes the prescribing decision.
- 1NewSelf shows a price on its own site before asking anything about you, so you can compare it with other sellers before you start a questionnaire.
- 2Ask NewSelf which pharmacy fills the prescription before you pay. The pharmacy's name is what lets you check its license.
- 3The monthly price includes the medication, clinician visits and shipping.
- Lowest ongoing monthly price: semaglutide $100, tirzepatide $144. That leaves out membership fees, first-month rates and insurance copays.
- NewSelf serves 49 of 50 states, so check that yours is one of them.
- The FDA has issued NewSelf a warning letter. It is covered in the enforcement section below; read what it alleges before you decide.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Contacting NewSelf
- Phone
- 1-855-606-5232
- NewSelf offers email support
- Hours
- 24/7
Cancelling NewSelf
Taken from the terms NewSelf publishes. Terms change, so check the current policy before you subscribe.
- Cancel any time
- Yes
- Minimum commitment
- None
- Refund policy
- Not published by the seller
GLP-1 medications NewSelf offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
All dosages same price
All dosages same price
Check the price yourself before you pay
Every figure here was read off NewSelf's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide costs $100 a month, 46% below the $185 median for compounded semaglutide across the sellers we compare
- Tirzepatide costs $144 a month, 42% below the $250 median for compounded tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price stays the same as your dose goes up
- The monthly price includes the medication, clinician visits and shipping
- Serves 49 states
Against it
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- The FDA has issued NewSelf a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What NewSelf charges
The standing price at NewSelf is $100/month, unchanged as the dose goes up. That sits at the affordable end of what we see. Flat dose pricing matters more than it sounds: on a tiered plan the bill grows with the dose, so the figure that got you to sign up is not the one you end up paying.
- Compounded semaglutide: $100/month
- Compounded semaglutide: $135/month
- Compounded tirzepatide: $144/month
- Compounded tirzepatide: $225/month
For compounded semaglutide, the median across the sellers we compare is $185/month, so NewSelf's $100 is genuinely below the middle, not just advertised that way.
bmiMD dispenses semaglutide and tirzepatide from $99/month, which makes it the fair comparison to run before you commit here.
What NewSelf dispenses
NewSelf prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product: the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
Safety and disclosure
NewSelf tells you its price before you start the medical questionnaire, that it treats patients in all 50 states, and that its pharmacy is accredited. The FDA has issued NewSelf a warning letter, summarized at the top of this page. A letter flags a problem rather than ruling a seller out, so read what it says before deciding what it means for you. Because the medication is compounded, the most useful question to ask at intake is which licensed pharmacy fills the prescription. If NewSelf will not tell you, treat that as a warning sign. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Everything listed here is compounded.
- You need insurance to cover the cost. Check whether NewSelf bills your plan before you start.
- A seller's regulatory history matters to you more than price. Read the warning letter summarized above before deciding.
It fits if
- the lowest standing monthly cost is what you are solving for
- you want the price to stop moving as your dose climbs
- you need access wherever you live
Our read
NewSelf competes on price, and at $100/month it competes well. The FDA warning letter is what to weigh against that, not a footnote to it. Whatever you decide, read the warning letter summarized at the top of this page first, and raise it with the clinician who would prescribe for you.
The Bottom Line
NewSelf falls below our bar on oversight: the FDA has issued it a warning letter. Read the breakdown below before you give it money.
Before you pay NewSelf
Starting at $100 a month. Check today's price, then start the intake.
Where NewSelf is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these three counts, another seller does better.
- If you need the FDA-approved pen rather than a compounded vial, consider Sesame Care.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo).
- If you want a human checking in, not just a prescription, consider Oak.
Compare NewSelf head to head
The sellers closest to NewSelf on medication and price.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
NewSelf has an FDA warning letter on record, dated February 20, 2026
This letter concerns false & misleading claims/misbranded. A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this NewSelf review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See NewSelf's current pricing
Plans start at $100 a month. Whether you qualify is a clinician's decision, made after your intake.